Bioaxial Completes €1.9M Equity Funding

bioaxialBioaxial, a Paris, France-based developer of super-resolved fluorescence microscopy for the extended imaging of live cells, completed a €1.9m ($2.7m) equity funding.

Backers included Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and Viveris Management and other individual investors.

The company intends to use the funds to launch its first product, an optical microscopy module, which is expected in the second half of 2014.

Founded in 2010 by by Gabriel Sirat and Louis-Philippe Braitbart (CEO), Bioaxial is developing imaging instruments for fluorescence microscopy that allow extended imaging of live cells with an improved resolution. Tested at the Institut Pasteur for the last 12 months, the company’s module allows observation of living cells in super-resolution over time without damaging them and adapt as an add-on for commercial microscopes.
Bioaxial, which has filed four patents and has acquired a fifth, currently employs five people.



Join the discussion